- Synthesis of carbon-11 labeled sulfonanilide analogues as new potential PET agents for imaging of aromatase in breast cancer
-
Aromatase is a particularly good target in the treatment of estrogen receptor positive breast cancer. Novel carbon-11 labeled sulfonanilide analogues, N-[11C]methyl-N-(2-alkyloxy-4-nitrophenyl)-methanesulfonamide s ([11C]3a-f, alkyl
- Wang, Min,Lacy, Gabrielle,Gao, Mingzhang,Miller, Kathy D.,Sledge, George W.,Zheng, Qi-Huang
-
p. 332 - 336
(2007/10/03)
-
- SULFONANILIDE ANALOGS AS SELECTIVE AROMATASE MODULATORS
-
Compounds and methods suppressing aromatase activity expression in cancer cells. Provided are compounds are those of formula I: wherein R1 may be alkyl, cycloakyl, haloalkyl, aryl, substituted aryl, haloaryl, alkoxy, alkylaryl, and arylalkyl; R2 is H, alk
- -
-
-
- Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition
-
Aromatase is a particularly attractive target in the treatment of estrogen receptor positive breast cancer. Aromatase levels in breast cancer cells are enhanced by prostaglandins and reduced by COX inhibitors. The synthesis and biological evaluation of a
- Su, Bin,Diaz-Cruz, Edgar S.,Landini, Serena,Brueggemeier, Robert W.
-
p. 1413 - 1419
(2007/10/03)
-
- Method for the treatment and prevention of cachexia
-
Cachexia, including anorexia and other forms of weight loss, is a frequent complication of acute and chronic infections, and result from induction of cytokines, prostaglandins, and other inflammatory mediators that are critical for pathogen elimination. The present invention includes methods for the treatment or prevention of cachexic conditions while maintaining the production of factors essential for infection control through the administration of an effective amount of a cyclooxygenase-2 selective inhibiting compound.
- -
-
-
- Antiangiogenic combination therapy for the treatment of cancer
-
The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective COX-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.
- -
-
-
- Sulfonanilide compounds
-
Sulfonanilide compounds represented by the formula STR1 wherein R1 is a lower alkyl group or a trifluoromethyl group, R2 is a cycloalkylidenemethyl group, a group of the formula --A--R3 (wherein A is an oxygen atom, a sulf
- -
-
-